Compound Mifepristone Tablets

This product is a compound preparation composed of mifepristone and anorthrin. Mifepristone is an anti-progestogen drug at the receptor level. It has no progestogen, estrogen, androgen and anti-estrogen activity. It can bind to the progesterone receptor and has an affinity for the endometrial progesterone receptor that is 5 times stronger than progesterone. This product may mainly interfere with the implantation process of the fertilized egg by affecting the normal physiological changes during the implantation period of the endometrium, thereby reducing the implantation rate and avoiding pregnancy. Anorthrin is a progestogen contraceptive that can reduce the amount of cervical mucus secretion and increase the viscosity, which is not conducive to sperm penetration; it affects the normal development of the endometrium and is not conducive to the implantation of the fertilized egg; it affects the normal activity of the fertilized egg in the fallopian tube, causing the fertilized egg to enter the uterine cavity early, resulting in asynchrony with the endometrium and inhibiting implantation.

This product is a compound preparation, and its components are: each tablet contains 30 mg of mifepristone and 5 mg of anordrin.

This product is off-white to slightly yellow tablets.

This product can be used in combination with misoprostol tablets to terminate early pregnancy within 49 days of amenorrhea.

Take orally every morning on an empty stomach or 2 hours after a meal. Do not eat for 1 hour after taking the medicine. Take one tablet at a time, once a day, for two consecutive days.

There are mild nausea, vomiting, dizziness, fatigue, lower abdominal pain and other discomforts. Occasionally, a rash may occur. After taking misoprostol, there may be abdominal pain, vomiting, diarrhea in some women, and flushing, itching and numbness in the hands and feet.

1. Patients who are allergic to any of the components of this product are prohibited from using this product. 2. Patients with heart, liver, or kidney diseases, adrenal insufficiency, hypertension, cardiovascular disease, glaucoma, asthma, coagulation disorders, or long-term use of cortisone are prohibited from using this product. 3. Patients who are pregnant with an intrauterine device or suspected of ectopic pregnancy are prohibited from using this product.

Precautions for children: Children are prohibited from taking this drug. Precautions for pregnancy and lactation: It has not been determined whether mifepristone is secreted into breast milk, but many hormones with similar chemical structures can be secreted into breast milk. Since it has not been determined whether mifepristone has an effect on infants, you should consult a doctor to decide whether you should stop breastfeeding within a few days of taking the drug. Precautions for the elderly: There is still a lack of experience in using the drug in elderly patients.

1. This product should not be used with rifampicin, carbamazepine, griseofulvin, barbiturates, phenytoin sodium, non-steroidal anti-inflammatory drugs, and adrenocortical hormones. 2. If you are taking other medicines, please consult a doctor before using this product.

Keep in a dark, sealed, cool (not exceeding 20°C) and dry place.

Each tablet contains 30 mg of mifepristone and 5 mg of anordrin

Tentative 18 months

Wuhan Jiulong Renfu Pharmaceutical Co., Ltd.

• Founded in:

  2009-10-23

• Address:

  No. 77, Guanggu 7th Road, East Lake New Technology Development Zone, Wuhan

• Tax NO.:

  91420100695320448C

• Registered Funds:

  50.08 million yuan

• Email:

  Log in to view